Cobalt Bio-Development

Cobalt Bio-Development develops, markets and sell diagnostic tests to detect various cancers.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Philadelphia, PA, USA
  • Currency USD
  • Founded September 2010
  • Employees 8

Company Summary

Cobalt Bio-Development produces marketed diagnostic tests to detect various cancers. These tests are used by physicians or companies developing new cancer medicines as tools to make better treatment decisions. We in-license “proof of concept” tests from academia and private biotechnology companies through brokered exclusive agreements. We identify new opportunities, develops and commercialize products via an established network of vendors.

Team

  • Johnathan Schantz, MLAS, BS, SRS, LATg
    CEO

    Jonathan has more than 25 years managing drug development and research projects for numerous companies and institutions. His has worked with Johnson & Johnson, GlaxoSmithKline, Wyeth, Eli Lilly, Princeton University, Temple University, The Commonwealth Medical College, Wadsworth Institute, The Vaccine Technology and Genomic Institute. He founded Cobalt Bio-Science, a contract research organization, and is co-founder of Cobalt Bio-Development.

  • Jae Sly, PhD, MBA
    VP, Product Commercialization

    Jae has over 12 years biotechnology experience in diagnostic/pre-clinical therapeutics and large-scale manufacturing. She has over 500 cell lines, 48 recombinant proteins, 4 therapeutic proteins and 5 monoclonal antibodies to her credit. She has extensive experience in the commercial production of diagnostic assays and vaccine production. She has numerous contracts with both domestic and international companies and regulatory agencies.

  • Sophia Hsieh, PhD
    VP Licensing & Technology Transfer

    Sophia has project team leader experience in analytical support of drug development for ALZA Corporation, Eisai Pharmaceuticals and GlaxoSmithKline. She has marketing and business Development experience for FMC BioPolymer and Life Technologies. She most recently owned her own consulting group and has a large network of academic and commercial contacts for in-licensing diagnostics, medical devices and pharmaceuticals.

  • Charles Hauswald, MS, MBA
    COO

    Charles co-founded Cobalt Bio-Development and is responsible for overall strategic partnerships and operations. He is an experienced biochemist and healthcare administrator involved in over 100 INDs, 20 NDAs and 55 clinical trials for numerous clients and companies. He has worked with Searle, Monsanto, Pfizer, Sterling, WIL Research, ABC Labs, Qualia Clinical Services, Alliance Pharma, Sanofi, Dupont, Bristol Meyers Squibb, Wyeth, and the WHO.

  • David Halverson
    VP Sales & Marketing

    David has held senior level sales & marketing positions with numerous companies. He has worked with Covance, MPI Research, Huntingdon Life Sciences, Quintiles and PPD.

  • Daniel Flynn, PhD
    Reseacher

    Daniel is Associate Dean for Research in the College of Health Sciences at the University of Delaware. He held a similar position at The Commonwealth Medical College and was Professor and Deputy Director of the Mary Babb Randolph Cancer Center, West Virginia University. He has authored over 70 research articles and served on an editorial board, advisory committees to the NIH and AAMC. He is the Scientific Founder of Protea Biosciences.

  • Stephen Meltzer, MD
    Researcher, Physician

    Stephen is Professor of Medicine and Oncology at Johns Hopkins University (Gastroenterology) and Director of GI Early Detection Biomarkers Laboratory. His research interests are GI cancer and precancer biomarker discovery, development and validation. He has published 152 scientific papers, 1 book, and 139 abstracts. He is recipient of the Funderburg Award in Gastric Cancer Biology and membership in the American Society for Clinical Investigation.

  • Yuriko Mori, MD, PhD
    Researcher, Physician

    Yuriko is Assistant Professor of Medicine at Johns Hopkins University School of Medicine (Gastroenterology). She has authored 34 research articles and is recipient of the AGA Research Scholar Award and the CCFA Senior Research Award. Her research focuses upon Genome-wide search for novel cancer-related genes in gastric and colonic cancers utilizing microarray technologies and their potential as diagnostic biomarkers or therapeutic targets.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free